Accelerate Diagnostics, Inc. (AXDX)
Accelerate Diagnostics, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Tucson, AZ, US. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $859,918. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of -427.8%. Its beta of 0.22 implies it has historically moved less than the broad market.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Accelerate Diagnostics, Inc. is most often compared with the following Healthcare names: